About
Exero Medical develops a biodegradable wireless sensor for early detection of anastomotic leaks following GI surgery. The system is designed to prevent complications by warning physicians of potential leaks, allowing early intervention. Anastomotic leaks are a common, life-threatening complication of GI surgeries, such as colorectal and bariatric surgeries. Early detection before the clinical manifestation of an anastomotic leak is key to a favorable outcome, but diagnosis at this stage is difficult. This delay in diagnosis affects both mortality rates and economic burdens. Exero Medicals system deploys a sensor that continuously monitors the condition of the anastomosis area, enabling early detection and preventive action before the patients condition deteriorates. In December 2020, the FDA granted breakthrough device designation for Exero Medicals wireless system designed for the early detection of potentially lethal anastomotic leaks following gastrointestinal surgery.
Funding history · 5 rounds · $16.1M total
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- What is Exero Medical's primary focus?
- Exero Medical develops a biodegradable wireless sensor for the early detection of anastomotic leaks following gastrointestinal (GI) surgery, aiming to prevent complications through early physician warnings.
- When was Exero Medical founded and where is it headquartered?
- Exero Medical was founded in September 2018 and is headquartered in Or Yehuda, Israel.
- What significant regulatory milestone did Exero Medical achieve in December 2020?
- In December 2020, the FDA granted breakthrough device designation for Exero Medical's wireless system, designed for the early detection of anastomotic leaks after GI surgery.
- What was Exero Medical's most recent funding round, and who were the lead investors?
- In February 2025, Exero Medical raised $12.7 million in an undisclosed funding round. The lead investors were Tech Council Ventures, Longevity Venture Partners, and Edge Medical Ventures.
- What is the total amount of funding Exero Medical has raised to date?
- According to startupim data, Exero Medical has raised a total of $16.1 million USD.
- When did Exero Medical complete enrollment for its US pivotal study?
- In September 2025, Exero Medical completed enrollment of 222 patients for its US pivotal study, focused on the early detection of post-operative gastrointestinal surgery complications.
- When did Exero Medical enroll its 100th patient in its pivotal study?
- In December 2024, Exero Medical announced the enrollment of its 100th patient in a pivotal study to validate its technology for early detection of post-operative complications.
- When did Exero Medical launch its international pivotal study for post-gastrointestinal surgery monitoring?
- In May 2024, Exero Medical launched an international pivotal study for post-gastrointestinal surgery monitoring.
- What was the purpose of Exero Medical's multi-center safety and feasibility study of xBar?
- In March 2022, Exero Medical enrolled its first patient in a multi-center safety and feasibility study of xBar, its post-surgery tissue monitoring and diagnostic system.